Hygiene
Lymphatic filariasis
Lymphatic Filariasis Burkina Faso. Photo Marcus Perkins Fir GSK
Fact sheet Updated March 2017
Key facts
• Lymphatic filariasis impairs the lymphatic system and can lead to the abnormal enlargement of body parts, causing pain, severe disability and social stigma.
• 947 million people in 54 countries worldwide remain threatened by lymphatic filariasis and require preventive chemotherapy to stop the spread of this parasitic infection.
• In 2000 over 120 million people were infected, with about 40 million disfigured and incapacitated by the disease.
• Lymphatic filariasis can be eliminated by stopping the spread of infection through preventive chemotherapy with safe medicine combinations repeated annually for at least 5 years. 6.2 billion treatments have been delivered to stop the spread of infection since 2000.
• 351 million people no longer require preventive chemotherapy due to successful implementation of WHO strategies.
• A basic, recommended package of care can alleviate suffering and prevent further disability among persons living with disease caused by lymphatic filariasis.
The disease
Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system.
The painful and profoundly disfiguring visible manifestations of the disease, lymphoedema, elephantiasis and scrotal swelling occur later in life and can lead to permanent disability. These patients are not only physically disabled, but suffer mental, social and financial losses contributing to stigma and poverty.
Currently, 947 million people in 54 countries are living in areas that require preventive chemotherapy to stop the spread of infection.
The global baseline estimate of persons affected by lymphatic filariasis was 25 million men with hydrocele and over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. Eliminating lymphatic filariasis can prevent unnecessary suffering and contribute to the reduction of poverty.
Cause and transmission
Lymphatic filariasis is caused by infection with parasites classified as nematodes( roundworms) of the family Filariodidea. There are 3 types of these thread-like filarial worms:
• Wuchereria bancrofti, which is responsible for 90 % of the cases
• Brugia malayi, which causes most of the remainder of the cases
• Brugia timori, which also causes the disease.
Adult worms lodge in the lymphatic vessels and disrupt the normal function of the lymphatic system.. The worms can live for an average of 6 – 8 years and, during their life time, produce millions of microfilariae( immature larvae) that circulate in the blood.
Mosquitoes are infected with microfilariae by ingesting blood when biting an infected host. Microfilariae mature into infective larvae within the mosquito. When infected mosquitoes bite people, mature parasite larvae are deposited on the skin from where they can enter the body.
The larvae then migrate to the lymphatic vessels where they develop into adult worms, thus continuing a cycle of transmission.
Lymphatic filariasis is transmitted by different types of mosquitoes for example by the Culex mosquito, widespread across urban and semi-urban areas, Anopheles, mainly found in rural areas, and Aedes, mainly in endemic islands in the Pacific.
Symptoms
Lymphatic filariasis infection involves asymptomatic, acute, and chronic conditions. The majority of infections are asymptomatic, showing no external signs of infection. These asymptomatic infections still cause damage to the lymphatic system and the kidneys, and alter the body’ s immune system. When lymphatic filariasis develops into chronic conditions it leads to lymphoedema( tissue swelling) or elephantiasis( skin / tissue thickening) of limbs and hydrocele( scrotal swelling). Involvement of breasts and genital organs is
36 Africa Water, Sanitation & Hygiene • May- June 2017